




# LIFE SCIENCES BOOTCAMP SERIES

**Federal Contracting & Drug Pricing**

James W. Kim, Lead Partner, MWE Public Sector

April 27, 2021

[mwe.com](https://mwe.com)



# AGENDA

## Government Contracts

- Process and Structure
- Federal Funding & Assistance Types
- Key Compliance Obligations

## Federal Drug Pricing

- What is a Covered Outpatient Drug?
- Key Government Agreements for a COD Manufacturer
- Medicare, Medicaid & 340B

## Conclusion and Questions

# AN INTRODUCTION TO GOVERNMENT CONTRACTS



McDermott  
Will & Emery

# GOVERNMENT CONTRACTING PROCESS AND STRUCTURE

Why do business  
with the  
Government?



The United States Government spends more than \$500B in annual procurement



Recent Federal Legislation has expanded greatly the realm of Government funding programs, including CARES, EAA and ARP



Pending expansion in Public Health/Preparedness and Domestic Medical Supply is expected to further supplement Government funded awards

How are funds  
Awarded?




Government awards are generally funded through annual Appropriations to the Federal Agencies



Federal Agencies Award Contracts, Grants, CRADAs, OTAs and other forms of Federal Financial Assistance

# GOVERNMENT CONTRACTING PROCESS AND STRUCTURE



# 1. FEDERAL CONTRACTS

A Prime Contract is awarded by a Federal Agency based on appropriated funds to a Commercial Entity



- Prime Awards
- Basic ordering agreements
  - Indefinite Delivery/Indefinite Quantity
- Blanket Purchase Agreements
- Multiple Award Schedule Contracts
- Letter contracts
- Purchase/Task Orders
- Distribution and Pricing Agreement (DAPA)
- Sole Source Awards



Subject to statutory requirements, FAR/DFARS and other Agency supplemental regulations, Executive Orders and regulatory guidance

## 2. FEDERAL GRANTS

Grants are used to Fund non-Government entities and individuals

- Used to carry out a public purpose authorized by a law of the United States (see 31 U.S.C. 6101(3)); and
- Not to acquire property or services for the Federal awarding agency or pass-through entity's direct benefit or use

Subject to Statutes, Regulations (Uniform Guidance (Title 2 of the CFR)), Executive Orders and official guidance

- FFATA Reporting
- Single Audit Requirement
- Allowability & Allocability

# 3. COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENTS (CRADA)

## CRADA Defined:

- A CRADA is an agreement between one or more Federal laboratories and one or more non-Federal parties
- The Government provides its laboratories and may provide personnel, services, facilities, equipment, intellectual property, or other resources but **no funds to non-Federal parties (e.g. private companies)**
- Non-Federal parties may provide funds, personnel, services, facilities, equipment, intellectual property, or other resources
- Purpose is the conduct of specified research or development efforts which are consistent with the missions of the laboratory

## When to use a CRADA:

- Private company contributes funding to research or requests IP rights
- Research project involves collaboration between government and private sector researchers
- Personnel, services, facilities, or equipment are to be supplied by the government, private company, or both



## 4. OTHER TRANSACTION AUTHORITY



OTA is the term commonly used to refer to the authority of the DoD to carry out certain prototypes, research, and production projects.




Other Transaction authorities were created to give DoD the flexibility necessary to adopt and incorporate business practices that reflect commercial industry standards and best practices into its award instruments (See 10 U.S.C. 2371b)



The DoD has permanent authority to award OT for (1) Research, (2) Prototype, and (3) Production Purposes.

## 5. OTHER FEDERAL FINANCIAL ASSISTANCE EXAMPLES



Provider Relief  
Fund


Paycheck  
Protection  
Program

Government  
Loans (Main  
Street Loan  
Program / SBA)

Direct  
Appropriations

Interest  
Subsidies

# PAYMENT/COST STRUCTURE OPTIONS



# KEY COMPLIANCE REQUIREMENTS

# FAR CLAUSES FOR GOVERNMENT CONTRACTS

## Key sources of regulatory requirements for Commercial Item Contracts

- [52.212-4](#) Contract Terms and Conditions-Commercial Items.
- [52.212-5](#) Contract Terms and Conditions Required to Implement Statutes or Executive Orders-Commercial Items.

Note: Certain FAR clauses, *per their language*, are required to be “flowed down” to subcontractors

# COMPLIANCE REQUIREMENTS FOR GOVERNMENT CONTRACTS

Applicability of Novation  
Agreements (FAR  
42.1204)

Prohibition on Contracting  
for Certain  
Telecommunications and  
Video Surveillance  
Services or Equipment  
(FAR 52.204-25)

Contractor Code of  
Business Ethics and  
Conduct (FAR 52.204-25)

Small Business  
Subcontracting Plan (FAR  
52.219-9)

Equal  
Opportunity (E.O.11246)  
(FAR 52.222-26)

Trade Agreements (FAR  
52.225-5)

Termination for  
Convenience (FAR  
52.249-2)

Recordkeeping  
Requirements (FAR 4.7,  
False Claims Act,  
Contract Disputes Act)

# ADDITIONAL COMPLIANCE REQUIREMENTS FOR VA FSS CONTRACTORS

Price Reduction  
Clause

Industrial Funding  
Fee

Mass Modifications

Trade Agreements  
Act \*

Distribution and  
Availability

# CERTAIN PROVISIONS CAN TRIGGER ADDITIONAL COMPLIANCE

Certified  
Cost or  
Pricing data  
(FAR  
15.403,  
52.215-21,  
FAR 52.215-  
19)

Basic  
Safeguardin  
g of  
Covered  
Contractor  
Information  
Systems  
(FAR  
52.204-21)

Safeguardin  
g Covered  
Defense  
Information  
and Cyber  
Incident  
Reporting  
(DFARS  
252.204-  
7012)

Notice of  
NIST SP  
800-171  
DoD  
Assessment  
(DFARS  
252.204-  
7019)

Small  
Business  
Set Aside  
(FAR  
52.219-6,  
52.219-7,  
52.219-19)

Cost  
Accounting  
Standards  
(FAR  
52.230-2)



# TOP 5 TIPS ON DOING BUSINESS WITH THE GOVERNMENT

1. Focus on the Mission
2. Doing business with the USG is bound by statute and regulation. These requirements cannot be negotiated generally, but can be addressed structurally
3. Understanding your statutory, regulatory and performance obligations are paramount
4. Be proactive regarding risk assessment and mitigation related to audit risk, compliance risk and liability exposure
5. Know your customer and engage thoughtfully – relationships are critical

# FEDERAL DRUG PRICING

# WHAT IS A COVERED OUTPATIENT DRUG (COD)?

- Under Section 1927(k) of the Social Security Act a “covered outpatient drug” is defined, in part, as
  - a drug which is approved for safety and effectiveness as a prescription drug under section 505 or 507 of the Federal Food Drug and Cosmetic Act or which is approved under section 505(j) of such Act



# WHAT IS **NOT** A COD?

## Not “Covered Outpatient”

- Any drug, biological product, or insulin provided as part of or incident to and in the same setting as certain services (and for which payment may be made as part of that service instead of as a direct reimbursement for the drug)

## Not a “Covered Drug”


- Any drug product, prescription or over-the-counter (OTC), for which an NDC number is not required by the FDA
- Any drug product for which a manufacturer has not submitted to CMS evidence to demonstrate that the drug product satisfies the criteria in the COD definition
- Any drug product or biological used for a medical indication which is not a medically accepted indication; or
- Over-the-counter products that are not drugs

# WHAT AGREEMENTS ARE APPLICABLE TO A COD?

- National Medicaid Drug Rebate Agreement (NDRA)
- Pharmaceutical Pricing Agreement (PPA)
- Federal Supply Schedule (FSS) Agreement



# COVERED OUTPATIENT DRUG: KEY FEDERAL AGREEMENTS



# NATIONAL MEDICAID DRUG REBATE AGREEMENT (NDRA)

If a manufacturer's drug is a COD, the drug is covered by Medicaid if the manufacturer participates in the Medicaid Drug Rebate Program ("MDRP") by entering into a NDRA

Under the MDRP, the manufacturer agrees to provide Rebates to the state Medicaid agency for CODs

Medicaid Rebates are calculated based on formula. See 42 U.S. Code § 1396r-8(c).

# KEY MANUFACTURER'S RESPONSIBILITIES UNDER NDRA

Calculate and report all required pricing data on every COD by NDC

Calculate a URA and make a rebate payment in accordance with each calculated URA to each State Medicaid Agency

Report all CODs and corresponding drug product, pricing, and related data to HHS upon entering into the NDRA and update as necessary

Report quarterly pricing data to HHS for all CODs

Report information including monthly AMPs and monthly AMP units for all CODs

Make rebate payments no later than 30 days after receiving the state rebate invoice

Make rebate payments on all of its CODs for as long as the agreement is in force and state utilization data reports that payment was made for that drug, regardless of whether the manufacturer continues to market the drug.

Keep records of data and other material from which the AMP calculations and best price were derived and make such records available to HHS upon request.



# PHARMACEUTICAL PRICING AGREEMENT (PPA)

A PPA must be signed by a manufacturer as a condition of participating in the Medicaid program

Section 340B requires a manufacturer that sells a COD to eligible entities to sign a PPA with the Secretary of Health and Human Services (HHS) in which the manufacturer agrees to charge a price for CODs that will not exceed the AMP decreased by a rebate percentage

# OTHER MANUFACTURER'S RESPONSIBILITIES UNDER PPA

Submit to HHS a list of the CODs, the AMP, baseline AMP, and the best price of such CODs

Retain all records related to the above for at least 3 years from the date of creation

Afford HHS reasonable access to records relevant to the manufacturer's compliance with the terms of the PPA

Permit CMS to share AMP and unit rebate amount submitted under the MDRP


Participate in the HRSA Prime Vendor Program \*

# VA FEDERAL SUPPLY SCHEDULE (FSS) CONTRACT

A manufacturer of CODs must offer those drugs to FSS in order to receive FHCP reimbursement (including Medicare/Medicaid), regardless of whether the drugs are purchased through the FSS

Prices on the FSS contract are determined based on the interplay of statutory requirements and terms of the FSS contract (including incorporated regulations)

# VA FEDERAL SUPPLY SCHEDULE (FSS) CONTRACT



Drug manufacturers must make CODs available for sale on an FSS contract at statutorily-capped pricing, known as the Federal Ceiling Price (FCP), to “Big Four” agencies (VA, DoD, Public Health Service (PHS) (including Indian Health Services) and the United States Coast Guard)

Other Government Agencies (OGAs) and other eligible FSS purchasers are not entitled to FCP, so VA allows manufacturers to decide whether to extend FCPs to OGAs

# SINGLE VS DUAL PRICING

## Single Pricers

- Maintain single price list
- Voluntarily provide FCP (or lower) pricing to all FSS-eligible purchasers as the FSS “contract price”

## Dual Pricers

- Establish two prices: (1) Big Four price capped at FCP and (2) OGA negotiated price that serves as the FSS contract price

# MEDICARE, MEDICAID AND 340B

# MEDICARE DRUG COVERAGE, REIMBURSEMENT AND PAYMENT

## Medicare Part A

- Pays for institutional care using prospective payment systems (PPS)
- Under PPS, Medicare makes a single payment to the facility for all care related to the encounter
- Drugs are not typically separately paid, with some limited exceptions


## Medicare Part B

- Pays on a “fee for service” basis for drugs administered by a physician in their office and for some drugs administered in a hospital outpatient department or clinic
- Separate payment is generally based on average sales price (ASP) methodology

## Medicare Part D


- Medicare Parts A and B do not cover “self-administered” drugs
- Coverage is only available through Medicare Part D
- Payment rates and coverage vary by plan

# MEDICAID DRUG PAYMENT





# 340B PROGRAM



# Q&A | CONCLUSION



**James W. Kim, Lead Partner, MWE  
Public Sector**

**[JaKim@mwe.com](mailto:JaKim@mwe.com)**

**202-756-8386**

This material is for general information purposes only and should not be construed as legal advice or any other advice on any specific facts or circumstances. No one should act or refrain from acting based upon any information herein without seeking professional legal advice. McDermott Will & Emery\* (McDermott) makes no warranties, representations, or claims of any kind concerning the content herein. McDermott and the contributing presenters or authors expressly disclaim all liability to any person in respect of the consequences of anything done or not done in reliance upon the use of contents included herein.

\*For a complete list of McDermott entities visit [mwe.com/legalnotices](http://mwe.com/legalnotices).

©2021 McDermott Will & Emery. All rights reserved. Any use of these materials including reproduction, modification, distribution or republication, without the prior written consent of McDermott is strictly prohibited. This may be considered attorney advertising. Prior results do not guarantee a similar outcome.